Valuation: Fortress Biotech, Inc.

Market Cap	62.7M 56.82M 52.55M 47.42M 89.36M 5.91B 92.51M 631M 250M 3.16B 235M 230M 10.02B	P/E 2026 *	0.74x	P/E 2027 *	-1.88x
Enterprise Value	62.7M 56.82M 52.55M 47.42M 89.36M 5.91B 92.51M 631M 250M 3.16B 235M 230M 10.02B	EV / Sales 2026 *	0.8x	EV / Sales 2027 *	0.55x
Free-Float	76.1%	Yield 2026 *	-	Yield 2027 *	-

* Estimated data More valuation ratios

Latest news: Fortress Biotech, Inc.

11-13	Fortress Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI
11-13	Fortress Biotech, Inc., Q3 2026 Earnings Call, Nov 12, 2026
10-02	Fortress Biotech, Inc. Repays Remaining $15 Million Outstanding Principal Under Oaktree Agreement	CI
08-14	Fortress Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-13	Fortress Biotech, Inc., Q2 2026 Earnings Call, Aug 12, 2026
05-15	Fortress Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-21	Journey Medical Corporation secures contract with third major GPO for Emrosi	RE
04-01	Fortress Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-31	Fortress Biotech Unit Closes $205 Million PRV Sale	MT
02-23	Fortress Biotech Subsidiary Agrees to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million	MT
01-13	Fortress Biotech shares hit near two-week low, last down 6.6%	RE
01-13	Fortress Biotech seen surging after FDA approval
01-13	Fortress Biotech and Cyprium Therapeutics Announce U.S. Fda Approval of Zycubo	CI

More news

Last Transcript: Fortress Biotech, Inc.

Fortress Biotech, Inc., Q3 2026 Earnings Call, Nov 12, 2026

11-13

More transcripts

Analysts' recommendations: Fortress Biotech, Inc.

01/10/25	Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101	CI
01/10/25	Fortress Biotech Shares Drop After FDA Letter for CUTX-101 Manufacturing Facility	DJ
01/10/25	Fortress Biotech and Cyprium Therapeutics announce an update on the NDA for CUTX-101	RE
19/03/24	Alliance Global Partners Initiates Fortress Biotech at Buy Rating With $5 Price Target	MT
29/11/23	Roth MKM Lowers Price Target on Fortress Biotech to $15 From $30, Maintains Buy Rating	MT

More recommendations

Press Releases: Fortress Biotech, Inc.

09-09	Journey Medical Corporation to Participate in September 2026 Investor Conferences	AQ
09-08	Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference	AQ
08-14	Fortress Biotech: Q2 Earnings Snapshot	AQ
08-14	Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights	AQ
08-13	Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights	AQ

More press releases

News in other languages: Fortress Biotech, Inc.

01-13	Fortress Biotech attendu en forte hausse après une approbation de la FDA
29/09/21	MÄRKTE USA/Nur maue Erholung - Belastungsfaktoren bleiben
29/09/21	MÄRKTE USA/Moderate Erholung von Vortagesabsturz
30/09/20	Israël limite les manifestations dans le cadre de mesures sanitaires
30/09/20	France : l'inflation a ralenti à 0,1% sur un an en septembre

More news

Managers and Directors: Fortress Biotech, Inc.

Manager	Title	Age	Since
Lindsay Rosenwald CEO	Chief Executive Officer	71	20/12/2013
Xiao Qin Lu DFI	Director of Finance/CFO	51	22/02/2012
David Jin DFI	Director of Finance/CFO	36	16/08/2022

Director	Title	Age	Since
Jimmie Harvey BRD	Director/Board Member	74	01/12/2008
Lindsay Rosenwald CHM	Chairman	71	20/12/2013
J. Jay Lobell BRD	Director/Board Member	63	01/06/2006

More insiders

Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13RÎ±2 CAR T Cell Program for Glioblastoma), and others.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
13/11/26	$1.880	-5.53%	310,605
12/11/26	$1.990	-1.00%	297,958
11/11/26	$2.010	+5.24%	382,208
10/11/26	$1.910	-4.02%	179,228
09/11/26	$1.990	+7.57%	289,754

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.880USD

Average target price

5.000USD

Spread / Average Target

+165.96%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Fortress Biotech, Inc.

Revisions to estimates

Quarterly earnings, Rate of surprise

Rate of surprise - EPS - Quarterly - Fortress Biotech, Inc.

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Nasdaq 01:00:00 14/11/2026 +04			5-day change	1st Jan Change
1.880 ^USD	-5.53%		+1.62%	-48.63%

Markets		Quality
Nasdaq	FBIO	Delayed
CBOE	FBIO	Real-time

1 day	-5.53%
1 week	+1.62%
Current month	-2.08%
1 month	-3.59%
3 months	-36.91%
6 months	-15.70%
Current year	-48.63%

1 week	1.76	2.06
1 month	1.76	2.07
Current year	1.76	4.53
1 year	1.76	4.53
3 years	1.3	4.53
5 years	1.24	52.63
10 years	1.24	91.5

Date	Insider	Type	Main position	Quantity	% Market Cap.
01/10/26	David Jin	Free	Chief Financial Officer	1,190	0.0036%
01/04/26	David Jin	Free	Chief Financial Officer	2,967	0.0096%
18/03/26	Lindsay Rosenwald	Free	Chief Executive Officer	475,424	1.5318%

Fortress Biotech, Inc. Stock

Stocks

FBIO

US34960Q3074

Pharmaceuticals

Valuation: Fortress Biotech, Inc.

Chart: Fortress Biotech, Inc.

Latest news: Fortress Biotech, Inc.

Last Transcript: Fortress Biotech, Inc.

Analysts' recommendations: Fortress Biotech, Inc.

Press Releases: Fortress Biotech, Inc.

News in other languages: Fortress Biotech, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Fortress Biotech, Inc.

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly earnings, Rate of surprise

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FORTRESS BIOTECH, INC.	-5.53%	+1.62%	-24.50%	+40.30%	62.7M
ELI LILLY AND COMPANY	+1.26%	+6.61%	+41.12%	+135.59%	1,286B
JOHNSON & JOHNSON	+0.79%	+3.45%	+46.35%	+93.56%	688B
ABBVIE INC.	+0.20%	+1.28%	+27.01%	+112.80%	521B
ROCHE HOLDING AG	-0.44%	+3.69%	+39.60%	+69.51%	386B
MERCK & CO., INC.	+0.55%	+0.70%	+59.00%	+44.20%	364B
NOVARTIS AG	-0.12%	+0.74%	+26.78%	+58.43%	302B
ASTRAZENECA PLC	+0.37%	+0.37%	+3.62%	+36.44%	287B
AMGEN INC.	-0.30%	+1.14%	+38.59%	+74.61%	252B
GILEAD SCIENCES, INC.	+0.08%	+0.71%	+34.25%	+124.32%	208B
Average	-0.31%	+2.03%	+29.18%	+78.97%	429B
Weighted average by Cap.	+0.54%	+3.26%	+37.63%	+96.23%

	2026 *	2027 *
Net sales	78.79M 71.4M 66.04M 59.59M 112M 7.43B 116M 793M 315M 3.97B 296M 289M 12.6B	113M 103M 94.92M 85.65M 161M 10.68B 167M 1.14B 452M 5.7B 425M 416M 18.11B
Net income	88.25M 79.97M 73.97M 66.74M 126M 8.32B 130M 889M 352M 4.44B 331M 324M 14.11B	-37.81M -34.27M -31.69M -28.6M -53.89M -3.57B -55.79M -381M -151M -1.9B -142M -139M -6.05B
Net Debt	-	-